Entry inhibitors show promise as drugs

[LilHope2010]

Entry inhibitors like REP9 AC and Myrcludex-B are promising as they are the only drugs that offer a complete CURE for Hepatitis B compared to immune modulators like Pegasys and Anti-virals like Entecavir... I think more research and concentration should be diverted to release inhibitor drugs as they seem to be promising and appropriate....

[4est]

is possible to ask for some more details on Liv.52 Hb (clinical study ...).

I suggest that the rest of us we shall ask on other forums (chines forum or indian forums or ...)  to see if we found some one that use this liv.52 hb and had some results

[Cjb3695]

Interesting stuff, I feel like we need to get everyone in one community, to be able to speak as a whole!

[Cjb3695]

So after emailing Replicor. I recieved an email back today with some awnsers to the questions I asked them.

Here are some brief answers to your questions:

Why arent you guys being supported by hepatitis B organizations that people are donating thousands of dollars too?
They typically do not donate money outside of their countries.

Why are people still using antivirals when we have a possible cure infront of us?
Because our drug is not approved yet.

Why cant us HBV carriers donate money less then 25k to you guys to speed up the process of testing and releasing this drug?
We are looking into this possibility.

When do you think at this rate you guys are moving will this drug be available for the public to possibly get rid of their virus?
We guess at least 3 to 4 years. Could take longer.

Michel Bazinet

[StephenCastlecrag]

2 Therapeutic vaccines from China - both in Phase IIb
1 Therapeutic vaccine from Dynavax
1  Therapeutic vaccine from France
LB80380 - antivral.

[LilHope2010]

http://www.hepb.org/professionals/hbf_drug_watch.htm  
this link contains further details of the future drugs...

[studyforhope]

To understand the true chances of Myrcludex, several factors have to be considered. The sequences of the critical blocking preS1 peptide fragment, myristylated or stearylated, have been published and are available in the paper. Thus the exact  chemistry of the forthcoming drug is known to people who read the scientific literature.

Currently phase one toxicity studies are planned this summer. The next phase , a small proof of concept study with maybe 20 to 40 chronic HBv patients will hopefully start early next year. Myrcludex will be used at the dose of 1mg per subcutaneous injection as shown in the presentation by Locarnini.

Now here is when the problems will start; there is no simple way to see the effectiveness of this entry inhibitor, since the reduction of reinfection is no a measurable parameter,there is no easy test for it. If a patient has rapid turnover - severe hepatitis- a more rapid removal of infected cells can be assumed and here Myrcludex has paradoxically a higher chance to show its effectiveness by slowly reducing the viral load and parallel the surface antigen concentration.

In a low grade inflammation infection turnover half life can be many month and a measurable reduction could take years.